Literature DB >> 5514974

Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.

D E Schwartz, J Rieder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5514974     DOI: 10.1159/000220701

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


× No keyword cloud information.
  28 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.

Authors:  H C Jackson; K Biggadike; E McKilligin; O S Kinsman; S F Queener; A Lane; J E Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Synergistic antibacterial activity in vitro of trimethoprim and sulphonamides and the importance of pharmacokinetic properties for optimal therapy.

Authors:  J K Seydel; E Wempe
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  [Penetration of sulfamethoxazole and trimethoprim into the anterior chamber in humans (author's transl)].

Authors:  J Rieder; B Ellerhorst; D E Schwartz
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1974-03-22

Review 5.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

6.  Pharmacokinetics of sulfadiazine and trimethoprim in man.

Authors:  F Andreasen; L Elsborg; S Husted; O Thomsen
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

7.  Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.

Authors:  A E Cribb; B Tsui; R Isbrucker; R T Michael; C T Gillespie; J Brown-Bonomo; P Barrett; T Levatte; K W Renton
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors:  Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients.

Authors:  K Naber; H Vergin; W Weigand
Journal:  Infection       Date:  1981       Impact factor: 3.553

10.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.